David R.W.  Jayne net worth and biography

David Jayne Biography and Net Worth

Dr. David R. W. Jayne has been Professor of Clinical Autoimmunity in the Department of Medicine at the University of Cambridge since 2017. Dr. Jayne is a medical advisor to UK, U.S. and EU regulatory bodies, patient groups, and professional organizations. His work has been published in more than 500 peer-reviewed journal articles, book chapters, and reviews. He was elected the first President of the European Vasculitis Society in 2011 and co-chairs the EULAR task force on lupus nephritis. Dr. Jayne’s research includes investigator-initiated international trials and the introduction of newer therapies in vasculitis and SLE with collaborators on five continents. In 2021 he received the European Renal Association award for outstanding contribution to nephrology.

Dr. Jayne received his MB BChir in Surgery and Medicine from Cambridge University. He received postgraduate training at several London hospitals and Harvard University. He is a fellow of the Royal College of Physicians of London and Edinburgh, and the Academy of Medical Science. He is a certified nephrologist and an Honorary Consultant Physician at Addenbrooke’s Hospital, Cambridge, UK.

How do I contact David R.W. Jayne?

The corporate mailing address for Dr. Jayne and other Aurinia Pharmaceuticals executives is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. Aurinia Pharmaceuticals can also be reached via phone at 250-708-4272 and via email at [email protected]. Learn More on David R.W. Jayne's contact information.

Has David R.W. Jayne been buying or selling shares of Aurinia Pharmaceuticals?

David R.W. Jayne has not been actively trading shares of Aurinia Pharmaceuticals during the last quarter. Learn More on David R.W. Jayne's trading history.

Who are Aurinia Pharmaceuticals' active insiders?

Aurinia Pharmaceuticals' insider roster includes Jeffrey Bailey (Director), Matthew Donley (VP), Peter Greenleaf (CEO), Scott Habig (Chief Commercial Officer), Joseph Hagan (Director), Robert Huizinga (EVP), David Jayne (Director), Greg Keenan (Chief Medical Officer), Jill Leversage (Director), Michael Martin (Insider), Joseph Miller (CFO), Neil Solomons (Insider), and Kevin Tang (Director). Learn More on Aurinia Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Aurinia Pharmaceuticals?

In the last twelve months, Aurinia Pharmaceuticals insiders bought shares 3 times. They purchased a total of 1,300,000 shares worth more than $13,590,000.00. In the last twelve months, insiders at the biotechnology company sold shares 5 times. They sold a total of 343,898 shares worth more than $2,753,094.15. The most recent insider tranaction occured on August, 5th when Director Kevin Tang bought 200,000 shares worth more than $2,336,000.00. Insiders at Aurinia Pharmaceuticals own 12.2% of the company. Learn More about insider trades at Aurinia Pharmaceuticals.

Information on this page was last updated on 8/5/2025.

David R.W. Jayne Insider Trading History at Aurinia Pharmaceuticals

See Full Table

David R.W. Jayne Buying and Selling Activity at Aurinia Pharmaceuticals

This chart shows David R.W. Jayne's buying and selling at Aurinia Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aurinia Pharmaceuticals Company Overview

Aurinia Pharmaceuticals logo
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Read More

Today's Range

Now: $15.31
Low: $14.76
High: $15.35

50 Day Range

MA: $13.46
Low: $11.05
High: $16.37

2 Week Range

Now: $15.31
Low: $6.55
High: $16.48

Volume

1,073,274 shs

Average Volume

1,824,637 shs

Market Capitalization

$2.02 billion

P/E Ratio

27.34

Dividend Yield

N/A

Beta

1.42